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Correspondence
To the Editor:
We read with interest the article by Mahfoud and colleagues.1 They 
classified 346 patients with uncontrolled hypertension according to 
their 24-hour ambulatory blood pressure (BP; threshold reported in 
Methods, 130 mm Hg) into 303 with true-resistant hypertension and 
43 with pseudoresistant hypertension. Systolic BP in truly resistant 
patients averaged 172 and 154 mm Hg on office and 24-hour ambu-
latory measurement and 161 and 121 mm Hg in pseudoresistant 
patients. Mahfoud et al reported that renal denervation reduced office 
BP and improved aspects of ambulatory BP, commonly linked to car-
diovascular risk, in truly resistant patients, whereas renal denervation 
only reduced office BP in pseudoresistant hypertension. A decrease in 
BP, being subjected to placebo effects and regression to the mean, is 
always more pronounced with a higher starting level.2 In our opinion, 
the conclusions by Mahfoud et al were therefore predictable.
In our opinion, the information in the Mahfoud et al article is 
incomplete.1 First, the authors did not measure, but extrapolated, car-
diovascular risk in relation to the ambulatory BP. Second, the pro-
portions of patients at 3, 6, and 12 months of follow-up were only 
70.8%, 68.2%, and 26.0%, with no reason given for the substantial 
attrition rate. Third, the authors reported that no differences existed 
in medication reductions (P=0.524) or increases (P=0.399) between 
true-resistant and pseudoresistant patients but did not report the num-
ber of antihypertensive drug classes during follow-up. Further data on 
the long-term efficacy and safety of renal denervation in treatment-
resistant hypertension should be collected in the context of random-
ized, clinical trials.
The Mahfoud et al article is inconsistent in the stated methods and 
results. For instance, there is contradiction between the abstract and 
the Methods section as to whether daytime as opposed to 24-hour 
ambulatory BP was used to classify patients. The Results refer to 
Figure 4 as illustrating daytime BP, whereas it is 24-hour BP accord-
ing to the figure legend. Throughout the article, we found contradic-
tions in summary statistics, which we communicated to the editors 
of Circulation. Based on Table 3, Mahfoud et al concluded that renal 
denervation was equally effective in all subgroups. However, Table 
3 provides only the odds that office BP declined by ≥10 mm Hg but 
does not allow comparison of the BP responses between subgroups. 
Mahfoud et al combined data from 10 centers without adjusting for 
differences between centers. Finally, we2 share the concerns of the 
editorialist3 about the disproportionality between the responses in 
office and ambulatory BPs.
The Dr Mahfoud’s center did >600 renal denervation proce-
dures at a cost of 4500€ each.4 Health insurance in Germany, 
Sweden, Switzerland, and the Netherlands now covers renal dener-
vation. Reimbursement of this costly and invasive procedure rests 
on a single randomized, clinical trial5 and the CE (Conformité 
Européenne) label certification (KCE reports 158C available at 
https://kce.fgov.be). 
In conclusion, generating solid evidence proving the long-term 
efficacy and safety of renal denervation in treatment-resistant hyper-
tension remains a top research priority.2
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